JACC. Case reports · 2026
Cilostazol-Induced Digoxin Toxicity Presenting as Accelerated Idioventricular Rhythm and Recurrent Syncope.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Madanieh Sameh, Desai Drashti, Goedert Gianne Macedo, Shultz Joshua, Hussain Hafiz
Аннотация
BACKGROUND: Digoxin has a narrow therapeutic index, and toxicity may occur even with apparently normal serum levels, particularly when drug interactions alter its pharmacokinetics or pharmacodynamics.
CASE SUMMARY: A 77-year-old man with atrial fibrillation and heart failure developed accelerated idioventricular rhythm (AIVR) after cilostazol was initiated for peripheral arterial disease. Serum digoxin appeared therapeutic, but the sample was drawn >30 hours postdose, outside the appropriate sampling window. Digoxin was discontinued and AIVR resolved completely.
DISCUSSION: Cilostazol potentiates digoxin toxicity via P-glycoprotein inhibition (reduced renal clearance) and PDE-3 inhibition (elevated cAMP, enhanced calcium influx). This interaction is frequently overlooked despite cilostazol being commonly coprescribed with digoxin in older patients with peripheral arterial disease and atrial fibrillation.
TAKE-HOME MESSAGES: AIVR in a digoxin-treated patient should prompt toxicity evaluation regardless of serum levels. The cilostazol-digoxin interaction is under-recognized and warrants proactive monitoring when these agents are coprescribed.
CASE SUMMARY: A 77-year-old man with atrial fibrillation and heart failure developed accelerated idioventricular rhythm (AIVR) after cilostazol was initiated for peripheral arterial disease. Serum digoxin appeared therapeutic, but the sample was drawn >30 hours postdose, outside the appropriate sampling window. Digoxin was discontinued and AIVR resolved completely.
DISCUSSION: Cilostazol potentiates digoxin toxicity via P-glycoprotein inhibition (reduced renal clearance) and PDE-3 inhibition (elevated cAMP, enhanced calcium influx). This interaction is frequently overlooked despite cilostazol being commonly coprescribed with digoxin in older patients with peripheral arterial disease and atrial fibrillation.
TAKE-HOME MESSAGES: AIVR in a digoxin-treated patient should prompt toxicity evaluation regardless of serum levels. The cilostazol-digoxin interaction is under-recognized and warrants proactive monitoring when these agents are coprescribed.